These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 35437188)

  • 1. Evaluation of radiation safety of the newly established national New Zealand 177-Lutetium (177-Lu or Lutate) Peptide Receptor Radiation Therapy (PRRT) service, a palliative treatment for patients with metastatic neuroendocrine tumours.
    Davidson J; Hull A; Mead T; Lunt B; Stewart A
    J Med Imaging Radiat Sci; 2022 Jun; 53(2 Suppl):S22-S30. PubMed ID: 35437188
    [No Abstract]   [Full Text] [Related]  

  • 2. A genome-wide CRISPR/Cas9 screen identifies DNA-PK as a sensitiser to
    Waldeck K; Van Zuylekom J; Cullinane C; Gulati T; Simpson KJ; Tothill RW; Blyth B; Hicks RJ
    Theranostics; 2023; 13(14):4745-4761. PubMed ID: 37771787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective.
    Kolasińska-Ćwikła A; Łowczak A; Maciejkiewicz KM; Ćwikła JB
    Nucl Med Rev Cent East Eur; 2018; 21(2):. PubMed ID: 29741203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptide Receptor Radionuclide Therapy with
    Cullinane C; Jeffery CM; Roselt PD; van Dam EM; Jackson S; Kuan K; Jackson P; Binns D; van Zuylekom J; Harris MJ; Hicks RJ; Donnelly PS
    J Nucl Med; 2020 Dec; 61(12):1800-1805. PubMed ID: 32414949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of peptide receptor radionuclide therapy (PRRT) in advanced metastatic bronchial neuroendocrine tumours (NETs).
    Mirvis E; Toumpanakis C; Mandair D; Gnanasegaran G; Caplin M; Navalkissoor S
    Lung Cancer; 2020 Dec; 150():70-75. PubMed ID: 33075738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of 177Lu Peptide Receptor Radionuclide Therapy for the Treatment of Neuroendocrine Tumors: A Meta-analysis.
    Saravana-Bawan B; Bajwa A; Paterson J; McEwan AJB; McMullen TPW
    Clin Nucl Med; 2019 Sep; 44(9):719-727. PubMed ID: 31205149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors.
    Bodei L; Kidd M; Paganelli G; Grana CM; Drozdov I; Cremonesi M; Lepensky C; Kwekkeboom DJ; Baum RP; Krenning EP; Modlin IM
    Eur J Nucl Med Mol Imaging; 2015 Jan; 42(1):5-19. PubMed ID: 25273832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: A systematic review and meta-analysis.
    Strosberg J; Leeuwenkamp O; Siddiqui MK
    Cancer Treat Rev; 2021 Feb; 93():102141. PubMed ID: 33418096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of the available peptide receptor radionuclide therapy for neuroendocrine tumors: a meta-analysis.
    Dannoon SF; Alenezi SA; Elgazzar AH
    Nucl Med Commun; 2017 Dec; 38(12):1085-1093. PubMed ID: 28957840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term results of PRRT in advanced bronchopulmonary carcinoid.
    Mariniello A; Bodei L; Tinelli C; Baio SM; Gilardi L; Colandrea M; Papi S; Valmadre G; Fazio N; Galetta D; Paganelli G; Grana CM
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):441-52. PubMed ID: 26392198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Personalized
    Del Prete M; Buteau FA; Beauregard JM
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1490-1500. PubMed ID: 28361189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic complications of peptide receptor radionuclide therapy with Lutetium-177 and Yttrium-90 in patients with neuroendocrine neoplasm.
    Bober B; Saracyn M; Lubas A; Kolodziej M; Brodowska-Kania D; Kapusta W; Kaminski G
    Nucl Med Rev Cent East Eur; 2022; 25(1):54-61. PubMed ID: 35137938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimation of Absorbed Doses of Indigenously Produced "Direct-route" Lutetium-177-[
    Kamaldeep ; Loharkar S; Das T; Basu S; Banerjee S
    Cancer Biother Radiopharm; 2022 Apr; 37(3):214-225. PubMed ID: 34910891
    [No Abstract]   [Full Text] [Related]  

  • 14. The next generation of peptide receptor radionuclide therapy.
    Brabander T; Nonnekens J; Hofland J
    Endocr Relat Cancer; 2019 Aug; 26(8):C7-C11. PubMed ID: 31200364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course.
    Bergsma H; Konijnenberg MW; Kam BL; Teunissen JJ; Kooij PP; de Herder WW; Franssen GJ; van Eijck CH; Krenning EP; Kwekkeboom DJ
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):453-63. PubMed ID: 26419852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis.
    Thang SP; Lung MS; Kong G; Hofman MS; Callahan J; Michael M; Hicks RJ
    Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):262-277. PubMed ID: 28894897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Lutetium-Peptide Receptor Radionuclide Therapy in Inducing Prolonged Tumour Regression in Small-Bowel Neuroendocrine Tumours: A Case of Favourable Response to Retreatment after Initial Objective Response.
    Rinzivillo M; Prosperi D; Bartolomei M; Panareo S; Iannicelli E; Magi L; Panzuto F
    Oncol Res Treat; 2021; 44(5):276-280. PubMed ID: 33853072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lutetium-labelled peptides for therapy of neuroendocrine tumours.
    Kam BL; Teunissen JJ; Krenning EP; de Herder WW; Khan S; van Vliet EI; Kwekkeboom DJ
    Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1(Suppl 1):S103-12. PubMed ID: 22388631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptide Receptor Radionuclide Therapy for Pancreatic Neuroendocrine Tumours.
    Alsadik S; Yusuf S; Al-Nahhas A
    Curr Radiopharm; 2019; 12(2):126-134. PubMed ID: 30714538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours.
    Elston MS; Love A; Kevat D; Carroll R; Siow ZR; Pattison S; Boyle V; Segelov E; Strickland AH; Wyld D; Gauci R; Kennedy K; Ransom D;
    Cancer Med; 2021 Dec; 10(23):8405-8411. PubMed ID: 34697905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.